Atherosclerosis prevention for the next decade: Risk assessment beyond low density lipoprotein cholesterol

Canadian Journal of Cardiology

Volumn 14, Issue 6, 1998, Pages 841-851

  Lamarche, Benoît ^a   Lewis, Gary F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Apolipoprotein B; Atherosclerosis prevention; Hypertriglyceridemia; Ischemic heart disease; Risk assessment; Small dense LDL particles

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; OBESITY; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ARTERIOSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; MALE; RISK FACTORS; TRIGLYCERIDES;

EID: 0031825018     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Coutard M, Roullet JB, Chamouard C, et al. Diet-induced hyperlipoprotememia and lipid accumulation within spontaneous arterial lesions in the rat. Artery 1989;16:118-39.
2. van Ree JH, van den Broek WJ, Dahlmans VE, et al. Diet-induced hypercholesterolemia and atherosclerosis in heterozygous apolipoprotein E-deficient mice. Atherosclerosis 1994;111:25-37.
3. Shiomi M, Ito T, Tsukada T, et al. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol 1995;15:1938-44.
4. Aliev G, Mironov A, Cirillo R, et al. Evidence for the presence of early vascular lesions in newborn Watanabe heritable hyperlipidemic (WHHL) rabbits. Atherosclerosis 1993;101:17-24.
5. Bilheimer DW, Watanabe Y, Kita T. Impaired receptor-mediated catabolism of low density lipoprotein in the WHHL rabbit, an animal model of familial hypercholesterolemia. Proc Natl Acad Sci USA 1982;79:3305-9.
6. Mabuchi H, Koizumi J, Shimizu M, Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989,79:225-32.
7. Keys A. Coronary heart disease in seven countries. Circulation 1970;41:11-211.
8. Castelli WP. Epidemiology of coronary heart disease: the Framingham Study. Am J Med 1984;76:4-12.
9. Stamler J, Wentworth D, Neaton JD Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-8.
10. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 1979;90:85-91.
11. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
12. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
13. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
14. Gotto AM Jr. Reduction of coronary events: evidence from clinical trials. Curt Opin Lipidol 1995;6:345-7.
15. Jones PH. Trials of lipid-lowering therapy in primary prevention of coronary heart disease. Curr Opin Lipidol 1995;6:365-8.
16. Olsson AG, Pedersen T, Bergdahl B. Trials of lipid-lowering therapy in secondary prevention of coronary heart disease. Curr Opin Lipidol 1995;6:369-73.
17. Stamler J, Stamler R, Brown WV, et al. Serum cholesterol. Doing the right thing. Circulation 1993;88:1954-60.
18. Grundy SM. Small, dense LDL, atherogenic dyslipidemias, and the metabolic syndrome. Circulation 1997;95:1-4.
19. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1333-445.
20. Ginsburg GS, Safran C, Pasternak RC. Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with desirable total cholesterol levels. Am J Cardiol 1991;68:187-92.
21. Miller M, Setdler A, Kwiterovich PO, Pearson TA. Long-term prediction of subsequent cardiovascular events with coronary artery disease and "desirable" levels of plasma total cholesterol. Circulation 1992;86:1165-70.
22. Miller M, Mead LA, Kwiterovich PO, Pearson TA. Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease. Am J Cardiol 1990;65:1-5.
23. Genest JJ, McNamara JD, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary heart disease. Am J Cardiol 1991;67:1185-9.
24. Superko HR. Beyond LDL cholesterol reduction. Circulation 1996;94:2351-4.
25. Lamarche B, Després JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study). Am J Cardiol 1995;75.1189-95.
26. Lamarche B, Després JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Quebec Cardiovascular Study. Atherosclerosis 1996;119:235-45.
27. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation 1996;94:273-8.
28. 3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997;17:1098-105.
29. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb Vasc Biol 1991;11:2-14.
30. Austin MA. Plasma triglycerides as a risk factor for coronary heart disease. The epidemiologic evidence and beyond. Am J Epidemiol 1989;129:249-59.
31. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
32. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992;70:3H-9H.
33. Lewis GF, Steiner G. Hypertriglyceridemia and its metabolic consequences as a risk factor for atherosclerotic cardiovascular disease in non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 1996;12:37-56.
34. Davignon J, Cohn JS. Triglycerides: a risk factor for coronary heart disease. Atherosclerosis 1996;124:S57-64.
35. Gotto AM Jr. Hypertriglyceridemia: risks and perspectives. Am J Cardiol 1992;70:19H-25H.
36. Manninen V, Tenkanen L, Koshinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85:37-45.
37. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992;70:733-7.
38. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Relation of high TG-Iow HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol 1997;17:1114-20.
39. Assmann G. The lipid triad: toward improved risk discrimination. Lipid Digest 1993;11:3-8.
40. Reichl D, Miller NE. Pathophysiology of reverse cholesterol transport. Insight from inherited disorders of lipoprötein metabolism. Arterioscler Thromb Vasc Biol 1989;9:785-97.
41. Eisenberg S. High density lipoprotein metabolism. J Lipid Res 1984;25:1017-58.
42. Tall AR. Plasma cholesteryl ester transfer protein and high-density lipoproteins: new insights from molecular genetic studies. J Intern Med 1995;237:5-12.
43. Phillips AN, Davey Smith G. How independent are "independent" effects? Relative risk estimation when correlated exposures are measured imprecisely. J Clin Epidemiol 1991;44:1223-31.
44. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34:1255-74.
45. Quintao ECR. Is reverse cholesterol transport a misnomer for suggesting its role in the prevention of atheroma formation? Atherosclerosis 1995;116:1-14.
46. Clay MA, Newnham HH, Barter PJ. Hepatic lipase promotes a loss of apolipoprotein A-I from triglyceride-enriched human high density lipoproteins during incubation in vitro. Arterioscler Thromb 1991;11:415-22.
47. Zhong S, Goldberg IJ, Bruce C, Rubin E, Breslow JL, Tall AR. Human apoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice. J Clin Invest 1994;94:2457-67.
48. Lewis GF, Lamarche B, Uffelman KD, et al. Clearance of post-prandial and lipolytically modified human HDL in rabbits and rats. J Lipid Res 1997;38:1771-81.
49. Horowitz BS, Goldberg IJ, Merab J, et al. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 1993;91:1743-52.
50. Shen MM, Krauss RM, Lindgren FT, Forte TM. Heterogeneity of serum low density lipoproteins in normal humans subjects. J Lipid Res 1981;22:236-44.
51. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982;23:97-104.
52. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willet WC, Krauss RM. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917-21.
53. Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol 1994;5:395-403.
54. Austin MA, King MC, Vranizan KM, Newman B, Krauss RM. Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis. Am J Hum Genet 1988;43:838-46.
55. Tchernof A, Lamarche B, Prud'Homme D, et al. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity and hyperinsulinemia in men. Diabetes Care 1996;19:629-37.
56. Lamarche B, Tchernof A, Dagenais GR, Cantin B, Lupien PJ, Després JP. Small, dense LDL particles and the risk of ischemic heart disease. Prospective results from the Quebec Cardiovascular Study. Circulation 1997;95:69-75.
57. Austin MA. Genetic and environmental influences on LDL subclass phenotypes. Clin Genet 1994;46:64-70.
58. McNamara JR, Jenner JL, Li Z, Wilson PW, Schaefer EJ. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb Vasc Biol 1992;12:1284-90.
59. Lahdenperá S, Sane T, Vuorinen-Markkola H, Knudsen P, Taskinen MR LDL particle size in mildly hypertriglyceridemic subjects: no relation to insulin resistance or diabetes. Atherosclerosis 1995;113:227-36.
60. Beard CM, Barnard RJ, Robbins DC, Ordovas JM, Schaefer EJ. Effects of diet and exercise on qualitative and quantitative measures of LDL and its susceptibility to oxidation. Arterioscler Thromb Vasc Biol 1996;16:201-7.
61. Packard CJ. LDL subfractions and atherogenicity: an hypothesis from the University of Glasgow. Curr Med Res Opin 1996;13:379-90.
62. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidermia. Arterioscler Thromb Vase Biol 1996;16:763-72.
63. Deckelbaum RJ, Galeano NF. Small dense low density lipoprotein: formation and potential mechanisms for atherogenicity. Isr J Med Sci 1996;32:464-8.
64. Gibbons GF. Assembly and secretion of hepatic very-low-density lipoprotein. Biochem J 1990;268:1-13.
65. Ginsberg HN. Synthesis and secretion of apolipoprorein B from cultured liver cells. Curr Opin Lipidol 1995;6:275-80.
66. Sniderman AD, Cianflone K. Measurement of apoproteins: time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemtas. Clin Chem 1996;42:489-91.
67. Cortner JA, Le NA, Coates PM, Bennett MJ, Cryer DR. Determinants of fasting plasma triglyceride levels: metabolism of hepatic and intestinal lipoproteins. Eur J Clin Invest 1992;22:158-65.
68. Després JP, Tremblay A, Pérusse L, Leblanc C, Bouchard C. Abdominal adipose tissue and serum HDL-cholesterol: association independent from obesity and serum triglyceride concentration. Int J Obes 1988;12:1-13.
69. Després JP. Obesity and lipid metabolism: relevance of body fat distribution. Curr Opm Lipidol 1993;2:5-15.
70. Després JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arterioscler Thromb Vasc Biol 1990;10:497-511.
71. Kalkhoff RK, Hartz AH, Rupley D, Kissebah AH, Kelber S. Relationship of body fat distribution to blood pressure carbohydrate tolerance, and plasma lipids in healthy obese women. J Lab Clin Med 1983;102:621-7.
72. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Am J Physiol 1994;74:761-811.
73. Després JP, Moorjani S, Ferland M, et al. Adipose tissue distribution and plasma lipoprotein levels in obese women: importance of intra-abdominal fat. Arterioscler Thromb Vasc Biol 1989;9:203-10.
74. Despiés JP. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition. 1993;9:452-9.
75. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1495-507.
76. Haffner SM. The insulin resistance syndrome revisited. Diabetes Care 1996;19:275-7.
77. Lemieux S, Prud'Homme D, Moorjani S, et al. Do elevated levels of abdominal visceral adipose tissue contribute to age-related differences in plasma lipoprotein concentrations in men? Atherosclerosis 1995;118:155-64.
78. Laws A. Free fatty acids, insulin resistance and lipoprotein metabolism. Curr Opin Lipidol 1996;7:172-7.
79. Després JP, Lamarche B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-7.
80. Dagenais GR, Robitaille NM, Lupien PJ, et al. First coronary heart disease event rates in relation to major risk factors: Quebec cardiovascular study. Can J Cardiol 1990;6:274-80.
81. Campos H, Genest JJ, Blijlevens E, et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb Vasc Biol 1992;12:187-95.
82. Tornvall P, Karpe F, Carlson LA, Hamsten A. Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infection. Atherosclerosis 1991;90:67-80.
83. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-8.
84. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996;276:875-81.
85. Lamarche B, Tchemof A, Mauriège P, et al. Targeting individuals at high risk for ischemic heart disease: what could we benefit from measuring fasting insulin, apolipoprotein B and LDL particle size? Diabetes 1997;46(Suppl 1):45A.
86. MacIsaac AI, Thomas JD, Topol EJ. Toward the quiescent coronary plaque. J Am Coll Cardiol 1993;22:1228-41.
87. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991;34:457-62.
88. Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen activator inhibitory activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 1993;36:817-25.
89. Mussoni L, Mannucci L, Sirtori M, et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 1992;12:19-27.
90. Simpson HC, Mann JI, Meade TW, Chakrabarti R, Stirling Y, Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1983;i:786-90.
91. Patsch JR. Triglyceride-rich lipoproteins and atherosclerosis-Atherosclerosis 1994;110:S23-6.
92. Bittner V. Atherogenicity of postprandial lipoproteins and coronary heart disease. Endocrinologist 1994;4:359-72.
93. Lewis GF, O'Meara NM, Soltys PA, et al. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein metabolism. J Clin Endocrinol Metab 1991;72:934-44.
94. Karpe F, Bard JM, Steiner G, Carlson LA, Fruchart JC, Hamsten A. HDLs and alimentary lipemia. Studies in men with previous myocardial infarction at a young age. Arterioscler Thromb Vasc Biol 1993;13:11-22.
95. Nakamura H, Ikewaki K, Nishiwaki M, Shige H. Postprandial hypetlipemia and coronary artery disease. Ann NY Acad Sci 1995;748:441-6.
96. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: 12 year follow up of participants in the population study of women in Gothenberg, Sweden. Br Med J 1984;289:1257-61.
97. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Björntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow-up of participants in the study of men born in 1913. Br Med J 1984;288:1401-4.
98. Stokes J, Garrison RJ, Kannel WB. The independent contributions of various indices of obesity to the 22-year incidence of coronary heart disease: the Framingham heart study. In: Vague J, Björntorp P, Guy-Grand B, Rebuffé-Scrive M, Vague P, eds. Metabolic Complications of Human Obesities. Amsterdam: Elsevier, 1985:49-57.
99. Lemieux S, Prud'Homme D, Tremblay A, Bouchard C, Després JP. Anthropometric correlates of changes in visceral adipose tissue over 7 years in women. Int J Obes 1996;20:618-24.
100. Lemieux S, Prud'Homme D, Bouchard C, Tremblay A, Després JP. A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr 1996;64:685-93.
101. Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460-8.
102. Després JP, Lamarche B. Low-intensity endurance exercise training, plasma lipoproteins and the risk of coronary heart disease. J Intern Med 1994;236:7-22.
103. Després JP, Lamarche B. Effects of diet and physical activity on adiposity and body fat distribution: implications for the prevention of cardiovascular disease. Nutr Res Rev 1993;6:137-59.
104. Frohlich J, Fodor G, McPherson R, Genest J, Langner N. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyshpidemias: Interim report. Can J Cardiol 1998;14(Suppl A):17A-21A.